Lexeo Therapeutics (LXEO) Accumulated Depreciation & Amortization (2022 - 2026)
Lexeo Therapeutics recorded quarterly Accumulated Depreciation & Amortization of $814000.0 in Q1 2026, up 9.85% quarter-over-quarter from $741000.0 in Q4 2025, and up 52.43% year-over-year from $534000.0 in Q1 2025.
Lexeo Therapeutics' Accumulated Depreciation & Amortization history runs 5 years deep, the most recent figure standing at $814000.0 for Q1 2026.
- In Q1 2026, Accumulated Depreciation & Amortization rose 52.43% year-over-year to $814000.0; the TTM figure through Mar 2026 stood at $814000.0 (up 52.43% YoY), while the FY2025 annual figure was $741000.0, up 56.33% from the prior year.
- Accumulated Depreciation & Amortization came in at $814000.0 for Q1 2026 at Lexeo Therapeutics, up from $741000.0 in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $814000.0 in Q1 2026 to a low of $133000.0 in Q4 2022.
- A 5-year average of $520333.3 and a median of $530500.0 in 2024 frame the typical range for Accumulated Depreciation & Amortization.
- Across the five-year window, Accumulated Depreciation & Amortization soared 186.47% in 2023 and grew 9.51% in 2025, its largest moves.
- Lexeo Therapeutics' Accumulated Depreciation & Amortization stood at $133000.0 in 2022, then jumped by 186.47% to $381000.0 in 2023, then rose by 24.41% to $474000.0 in 2024, then surged by 56.33% to $741000.0 in 2025, then rose by 9.85% to $814000.0 in 2026.
- According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods registered $814000.0, $741000.0, and $668000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Lexeo Therapeutics | 392.12 Mn | 199.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 814,000.00 |
| Mar 31, 2026 | 814,000.00 |
| Dec 31, 2025 | 741,000.00 |
| Dec 31, 2025 | 741,000.00 |
| Sep 30, 2025 | 668,000.00 |
| Sep 30, 2025 | 668,000.00 |
| Jun 30, 2025 | 596,000.00 |
| Jun 30, 2025 | 596,000.00 |
| Mar 31, 2025 | 534,000.00 |
| Mar 31, 2025 | 534,000.00 |
| Dec 31, 2024 | 474,000.00 |
| Dec 31, 2024 | 474,000.00 |
| Sep 30, 2024 | 610,000.00 |
| Sep 30, 2024 | 610,000.00 |
| Jun 30, 2024 | 527,000.00 |
| Jun 30, 2024 | 527,000.00 |
| Mar 31, 2024 | 450,000.00 |
| Mar 31, 2024 | 450,000.00 |
| Dec 31, 2023 | 381,000.00 |
| Dec 31, 2023 | 381,000.00 |
| Sep 30, 2023 | 316,000.00 |
| Sep 30, 2023 | 316,000.00 |
| Dec 31, 2022 | 133,000.00 |
| Dec 31, 2022 | 133,000.00 |